TEST:

Quantitative BCR-ABL 2.0 Panel

Precipio’s BCR-ABL 2.0 assay is the only panel on the market that provides quantitative coverage of four clinically relevant breakpoints – p.190, p.210, p.203 and p.230. To the patient, this means a higher level of accuracy by providing broader testing coverage, ensuring they are put on the correct treatment. Precipio’s BCR-ABL assay can detect gene mutations as infrequent as 1 in 100,000. This is twice as sensitive as the next most sensitive qPCR assay on the market.